Peter Ellmark

21 – 30 of 59

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/a5d815ea-d85e-4ea6-be56-c1d4bc3350ae?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2019
Mark The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Kvarnhammar, Anne Månsson ; Veitonmäki, Niina ; Hägerbrand, Karin ^LU ; Dahlman, Anna ^LU ; Smith, Karin Enell ^LU ; Fritzell, Sara ^LU ; Von Schantz, Laura ^LU ; Thagesson, Mia ; Werchau, Doreen and Smedenfors, Kristine , et al. (2019) In Journal for ImmunoTherapy of Cancer 7(1).
- Contribution to journal › Article
2018
Mark Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
Hebb, Jonathan P.O. ; Mosley, Adriane R. ; Vences-Catalán, Felipe ; Rajasekaran, Narendiran ; Rosén, Anna ; Ellmark, Peter ^LU and Felsher, Dean W. (2018) In Cancer Immunology, Immunotherapy 67(1). p.47-60
- Contribution to journal › Article
2017
Mark Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Ellmark, Peter ^LU ; Mangsbo, Sara M. ; Furebring, Christina ^LU ; Norlén, Per ^LU and Tötterman, Thomas H. (2017) In Cancer Immunology and Immunotherapy 66(1). p.1-7
- Contribution to journal › Article
Mark Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
van Hooren, Luuk ; Sandin, Linda C ; Moskalev, Igor ; Ellmark, Peter ^LU ; Dimberg, Anna ; Black, Peter ; Tötterman, Thomas H and Mangsbo, Sara M (2017) In European Journal of Immunology 47(2). p.385-393
- Contribution to journal › Article
2016
Mark Selective FcγR engagement by human agonistic anti-CD40 antibodies
Ellmark, Peter ^LU ; Mangsbo, Sara M. and Lindstedt, Malin ^LU (2016) In Translational Cancer Research 5. p.839-841
- Contribution to journal › Debate/Note/Editorial
2015
Mark The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity.
Mangsbo, Sara M ; Broos, Sissela ^LU ; Fletcher, Erika ; Veitonmaki, Niina ; Furebring, Christina ; Dahlen, Eva ; Norlén, Per ^LU ; Lindstedt, Malin ^LU ; Totterman, Thomas H and Ellmark, Peter ^LU (2015) In Clinical Cancer Research 21(5). p.1115-1126
- Contribution to journal › Article
Mark Kick-starting the cancer-immunity cycle by targeting CD40
Ellmark, Peter ^LU ; Mangsbo, S. M. ; Furebring, C. ; Totterman, T. H. and Norlen, P. (2015) In OncoImmunology 4(7). p.1011484-1011484
- Contribution to journal › Debate/Note/Editorial
2014
Mark Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Sandin, Linda C ; Eriksson, Fredrik ; Ellmark, Peter ^LU ; Loskog, Angelica Si ; Tötterman, Thomas H and Mangsbo, Sara M (2014) In OncoImmunology 3(1). p.27614-27614
- Contribution to journal › Article
Mark Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
Sandin, Linda C ; Orlova, Anna ; Gustafsson, Erika ; Ellmark, Peter ^LU ; Tolmachev, Vladimir ; Tötterman, Thomas H and Mangsbo, Sara M (2014) In Cancer immunology research 2(1). p.80-90
- Contribution to journal › Article
2009
Mark Attovial-based antibody nanoarrays.
Ellmark, Peter ^LU ; Ghatnekar-Nilsson, Sara ^LU ; Meister, André ; Heinzelmann, Harry ; Montelius, Lars ^LU ; Wingren, Christer ^LU and Borrebaeck, Carl ^LU (2009) In Proteomics 9(24). p.5406-5413
- Contribution to journal › Article